Fosamax Patent History and Generic Alendronate Timeline

How Alendronate Works: Mechanism of Action

Alendronate sodium is a nitrogen-containing bisphosphonate that binds to hydroxyapatite crystals on bone surfaces undergoing active resorption. Once osteoclasts ingest the drug during bone resorption, alendronate inhibits farnesyl pyrophosphate synthase (FPPS), a key enzyme in the mevalonate pathway. This disrupts the prenylation of small GTPase signaling proteins, including Ras, Rho, and Rac, which osteoclasts need for cytoskeletal organization and survival 1.

The result is osteoclast apoptosis. Dead osteoclasts stop dissolving bone.

By suppressing osteoclast-mediated resorption while allowing osteoblast bone formation to continue relatively unchanged, alendronate shifts the remodeling balance toward net bone gain. Bone mineral density (BMD) at the lumbar spine increases by 5% to 8% over three years, and femoral neck BMD rises by approximately 3% to 4% over the same period 2. The drug's affinity for bone mineral is high enough that its skeletal half-life exceeds 10 years, meaning pharmacologic effects persist long after discontinuation. This property later became central to the concept of bisphosphonate "drug holidays," which the American Society for Bone and Mineral Research formally addressed in its 2016 task force report [3].

Oral bioavailability is extremely low, roughly 0.7% under fasting conditions. Anything in the stomach, including coffee, juice, or calcium supplements, can reduce absorption to near zero. This pharmacokinetic reality drove Merck's clinical development of both the dosing instructions (taken on an empty stomach with plain water, 30 minutes before food) and eventually the once-weekly formulation.

FDA Approval History and Early Patent Protection

The FDA approved alendronate sodium 10 mg daily tablets on September 29, 1995, under NDA 020560, for the treatment of osteoporosis in postmenopausal women 4. This approval relied primarily on data from the Phase III Fracture Intervention Trial (FIT), which enrolled 2,027 women with at least one vertebral fracture at baseline.

Merck held US Patent 4,922,007, covering the alendronate compound itself. Filed in 1988. Granted in 1990. This was the foundational intellectual property that protected the molecule from generic competition for nearly two decades. A second patent, US 4,621,077, covered certain pharmaceutical compositions containing alendronate and added another layer of exclusivity.

Between 1995 and 2001, Merck expanded the label to include:

• Treatment of osteoporosis in men (2000)
• Prevention of postmenopausal osteoporosis (1997)
• Treatment of glucocorticoid-induced osteoporosis (1999)
• Treatment of Paget's disease of bone (1995)

Each indication broadened alendronate's commercial footprint, and by 2000, Fosamax was generating over $1 billion annually in US sales 5.

The Once-Weekly Formulation and Patent Extension Strategy

Merck introduced the 70 mg once-weekly tablet in October 2000, supported by the FOSIT study and a key bioequivalence trial demonstrating that 70 mg weekly produced equivalent BMD gains to 10 mg daily over one year 6. The weekly formulation was covered under US Patent 5,994,329, filed in 1998 and granted in 1999, with an expiration date extending to 2012.

This move was strategically significant. Patients overwhelmingly preferred the once-weekly regimen. Adherence data from administrative claims showed that weekly dosing improved 12-month persistence by roughly 15 to 20 percentage points compared with daily dosing 7. Physicians rapidly shifted prescriptions to the 70 mg weekly tablet, which became the dominant formulation. By the time the compound patent expired, the market had largely transitioned to the weekly dose.

The weekly formulation patent gave Merck a potential four additional years of brand-only sales for the most commonly prescribed strength. Generic manufacturers, however, challenged both patents.

Patent Challenges and the Paragraph IV Litigation Wave

Generic drug manufacturers filed Abbreviated New Drug Applications (ANDAs) with Paragraph IV certifications alleging that Merck's patents were either invalid or would not be infringed by their generic products. Teva Pharmaceuticals and Barr Pharmaceuticals (later acquired by Teva) were among the first to file.

The legal battles centered on two questions. First, whether the compound patent claims were valid given prior art. Second, whether the once-weekly dosing patent could survive challenges to its obviousness.

Merck settled several of these suits. The terms varied, but the practical outcome was clear: generic alendronate sodium 10 mg daily tablets could launch upon expiration of the compound patent in February 2008, while the 70 mg weekly tablets faced a more complex timeline tied to the 1999 formulation patent 8.

A federal district court ultimately ruled portions of the weekly-dosing patent invalid, allowing generic 70 mg weekly alendronate to reach the market earlier than the 2012 expiration date would have allowed. Multiple manufacturers received final ANDA approvals for 70 mg weekly tablets between 2008 and 2010.

Generic Entry: February 2008 and Beyond

On February 6, 2008, the FDA approved the first generic alendronate sodium tablets. Teva and Barr were first to market, benefiting from their 180-day exclusivity period as first ANDA filers under the Hatch-Waxman Act. This exclusivity applied to the 70 mg weekly tablet 9.

The pricing impact was immediate. Brand Fosamax 70 mg weekly had been priced at approximately $90 to $100 per month at wholesale acquisition cost. Within six months of generic entry, prices for alendronate sodium 70 mg tablets dropped below $30. Within two years, as additional manufacturers entered, costs fell to under $10 per month at most retail pharmacies.

By 2010, over 20 generic manufacturers were producing alendronate sodium globally. Merck's Fosamax revenue fell from $3.2 billion at its peak in 2007 to under $500 million by 2010, a trajectory consistent with the typical branded-to-generic erosion curve for high-volume oral medications 10.

Today, generic alendronate sodium 70 mg tablets are available for as little as $4 per month through discount pharmacy programs.

Fosamax Plus D and Other Line Extensions

Merck attempted to extend the Fosamax franchise through combination products. Fosamax Plus D, which paired alendronate 70 mg with 2 to 800 IU (later 5 to 600 IU) of cholecalciferol (vitamin D3) in a single weekly tablet, received FDA approval in 2005 11.

This combination targeted the well-documented problem of vitamin D insufficiency among osteoporosis patients. Data from the original FIT trial population showed that approximately 30% of participants had serum 25-hydroxyvitamin D levels below 20 ng/mL at baseline. The combination product ensured a minimum weekly vitamin D supplement.

However, Fosamax Plus D never achieved dominant market share. Many physicians and patients preferred to dose vitamin D separately, titrating to individual needs. Generic alendronate paired with over-the-counter vitamin D3 supplements provided equivalent therapy at a fraction of the cost.

Merck also explored an effervescent tablet formulation (Binosto), which was approved in 2012 and marketed by Mission Pharmacal. This buffered formulation aimed to reduce esophageal irritation. But its higher price and the availability of cheap generic tablets limited adoption.

The FIT Trial: Clinical Foundation of Alendronate's Market Position

The Fracture Intervention Trial (FIT) remains the cornerstone of alendronate's evidence base 2. Published in JAMA in 1998, FIT enrolled 2,027 postmenopausal women aged 55 to 81 years with at least one baseline vertebral fracture (the vertebral fracture arm) and 4,432 women with low BMD but no prevalent fractures (the clinical fracture arm).

Key results from the vertebral fracture arm over 36 months:

• 47% relative risk reduction in new vertebral fractures (RR 0.53 to 95% CI 0.41 to 0.68)
• 51% reduction in hip fractures (RR 0.49 to 95% CI 0.23 to 0.99)
• 48% reduction in wrist fractures

The clinical fracture arm (published separately as FIT-2) showed a 44% reduction in vertebral fractures among women with T-scores at or below -2.5 but no prevalent fractures 12.

These results were what made alendronate a first-line treatment. No prior osteoporosis drug had demonstrated such broad fracture reduction across multiple skeletal sites in a single trial program. The FIT data also formed the basis for the World Health Organization's FRAX tool validation and informed the National Osteoporosis Foundation's treatment thresholds.

Dr. Dennis Black, the principal investigator of FIT, stated at the time: "The magnitude of vertebral fracture reduction with alendronate exceeded what many of us expected based on the BMD changes alone, suggesting effects on bone quality beyond simple density."

Long-Term Safety Data and the Patent-Era Legacy

During the patent-protected period, Merck accumulated extensive post-marketing safety data. The 10-year extension of the original FIT cohort (the FLEX trial) provided the longest prospective bisphosphonate data available 13. FLEX randomized 1,099 women who had taken alendronate for a mean of five years to continue for another five years or switch to placebo.

The FLEX results, published in JAMA in 2006, showed that:

• BMD gains were partially maintained for 3 to 5 years after discontinuation
• Vertebral fracture risk increased modestly after stopping (clinical vertebral fracture RR 0.45 for continuers vs. discontinuers)
• Non-vertebral fracture rates did not differ significantly between groups

These data supported the concept of bisphosphonate holidays for moderate-risk patients after 5 years of therapy and continued treatment for high-risk patients, a framework now endorsed by the American Association of Clinical Endocrinology (AACE) 14 and the Endocrine Society 15.

Rare adverse events that emerged during the patent era and post-marketing surveillance include osteonecrosis of the jaw (ONJ), estimated at 1 per 10,000 to 1 per 100,000 patient-years for oral bisphosphonates, and atypical femoral fractures (AFF), with incidence estimates of 3.2 to 50 per 100,000 person-years depending on duration of use 16.

Current Market Status and Prescribing Patterns (2026)

Alendronate sodium is now fully genericized. No active patents protect any formulation in the United States or European Union. The drug remains on the WHO Model List of Essential Medicines and is classified as first-line pharmacotherapy for osteoporosis by the AACE/ACE 2020 guidelines 14, the Endocrine Society 2019 guidelines 15, and NICE Technology Appraisal TA464.

Annual US prescriptions for alendronate exceed 10 million, making it the most prescribed bisphosphonate by a wide margin. Generic competition has driven prices so low that alendronate is included in most $4 generic lists at major US pharmacy chains.

For patients and prescribers, the practical consequence of the completed patent cycle is straightforward: alendronate 70 mg weekly costs less per year than a single brand-name dose of denosumab (Prolia), which carries a list price exceeding $1,800 per injection administered every six months. This cost differential influences treatment selection, particularly for patients without comprehensive insurance coverage.

The Endocrine Society's 2019 guideline recommends: "For most postmenopausal women at high fracture risk, we suggest initial treatment with bisphosphonates (alendronate, risedronate, or zoledronic acid) over denosumab, given cost-effectiveness, long track record, and the rebound risk associated with denosumab discontinuation" 15.

International Generic Availability and Biosimilar Context

Outside the United States, generic alendronate has been available even longer in some markets. The UK approved generic alendronate in 2005 under different patent rules. India, Brazil, and China have manufactured generic alendronate since the mid-2000s, with dozens of registered formulations.

Unlike biologic drugs such as denosumab, alendronate is a small-molecule chemical compound. Generic versions are approved through standard bioequivalence testing, not the biosimilar pathway. This distinction matters: small-molecule generics require only pharmacokinetic equivalence studies in healthy volunteers, while biosimilars require comparative clinical trials. The regulatory bar for generic alendronate approval is lower, which explains why so many manufacturers entered the market rapidly after patent expiry.

The WHO's inclusion of alendronate on its Essential Medicines List has facilitated procurement through international agencies. UNICEF and the Global Fund reference pricing typically places alendronate 70 mg weekly tablets at $0.03 to $0.10 per tablet in low- and middle-income countries 17.

Oral alendronate 70 mg taken once weekly, 30 minutes before the first meal of the day with a full glass of plain water while remaining upright, costs between $4 and $15 per month at US retail pharmacies and carries Level A evidence for vertebral, hip, and wrist fracture reduction in postmenopausal osteoporosis 2.